Drug intelligence / Profile preview

YR-G591

Development stage: Preclinical
Lead developer: Sichuan Enray Pharmaceutical Sciences
Modality: Small Molecules

Overview

YR-G591 is a preclinical-stage small molecule inhibitor of glutathione peroxidase 4 (GPX4) being developed by Sichuan Enray Pharmaceutical Sciences. As a derivative of YR-G346, YR-G591 is designed to precisely target the selenocysteine active site of the GPX4 protein, thereby blocking the glutathione regeneration pathway. This inhibition leads to the accumulation of lipid peroxides and triggers ferroptosis, a form of regulated cell death. YR-G591 is being investigated for its potential to enhance the sensitivity of tumor cells to ferroptosis for the treatment of cancer.

Targets

GPX4 (Glutathione peroxidase 4)

Beyond the preview

Go deeper on YR-G591.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YR-G591.